RecruitingPhase 2NCT05844046

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

Studying Leukoencephalopathy with calcifications and cysts

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Enrico De Toni
Intervention
durvalumab, tremelimumab, bevacizumab(biological)
Enrollment
83 target
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05844046 on ClinicalTrials.gov

Other trials for Leukoencephalopathy with calcifications and cysts

Additional recruiting or active studies for the same condition.

See all trials for Leukoencephalopathy with calcifications and cysts

← Back to all trials